Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xipayi Maizibizi is a traditional Uyghur medicine (a branch of Traditional Chinese Medicine) developed and manufactured by Shaanxi Dongtai Pharmaceutical. It is formulated as an oral capsule containing the extract of the fruit of *Apium graveolens* (celery seed), which is known in Uyghur medicine as Maizibizi. The preparation is traditionally used to warm the kidney, resolve cold phlegm, and promote diuresis. Clinically, it is primarily indicated for the treatment of chronic prostatitis and benign prostatic hyperplasia (BPH), particularly when symptoms include frequent urination, urgency, and painful urination associated with kidney deficiency and coldness. It is an approved pharmaceutical product in China, categorized under traditional medicine regulations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xipayi maizibizi.